07:00 , Apr 1, 2013 |  BC Week In Review  |  Clinical News

OHR/AVR118: Phase II data

An open-label, Canadian Phase II trial in 18 patients with stage III/IV solid tumors with cachexia showed that once-daily subcutaneous injections of 4 mL OHR/AVR118 missed the primary endpoint of improving weight gain at day...
08:00 , Dec 14, 2009 |  BC Week In Review  |  Clinical News

OHR118: Phase II data

Interim data from a Phase II trial in 11 patients showed that OHR118 produced weight stabilization or gain in 7 patients. Compared to baseline, OHR118 significantly improved total PG-SGA scores (p<=0.01), appetite (p<=0.01) and depression...
08:00 , Dec 7, 2009 |  BC Week In Review  |  Company News

Advanced Viral, Ohr endocrine, dermatology, ophthalmic news

Ohr updated its pipeline, which includes compounds from Advanced Viral and Genaera Corp. Ohr acquired AVR118 and AVR123 from Advanced Viral in March for $100,000 in cash, plus a $500,000 convertible debenture secured...
08:00 , Feb 2, 2009 |  BC Week In Review  |  Company News

Advanced Viral cancer, infectious news

Advanced Viral suspended operations because it could not secure financing. The company is in default on its secured convertible debentures to Y.A. Global Investments L.P., to whom it owes $2.2 million in principal and interest....
08:00 , Mar 3, 2008 |  BC Week In Review  |  Company News

Advanced Viral, Northeastern University deal

Advanced Viral and the university partnered to identify the mechanism of action of the company’s lead compound, AVR118. The peptide nucleic acid-type immunomodulator is in Phase II testing to treat cachexia in cancer patients....
08:00 , Feb 4, 2008 |  BioCentury  |  Product Development

Proteasome inhibitors on deck

Proteasome inhibitors on deck Company Product Indication Status Proteolix Carfilzomib (PR-171) Relapsed and refractory multiple myeloma (MM) Ph II Carfilzomib (PR-171) Relapsed solid tumors Ph Ib/II PR-047 oral Cancer Preclin Cephalon (NASDAQ:CEPH) CEP-18770 Solid...
08:00 , Dec 10, 2007 |  BC Week In Review  |  Company News

Advanced Viral management update

Advanced Viral Research Corp. (ADVR), Yonkers, N.Y.   Business: Cancer, Infectious   Hired: Vincent Gullo as CSO, formerly VP of drug discovery at Cetek Corp.; and Dallas Hughes as VP of research, formerly SVP of technology...
08:00 , Dec 10, 2007 |  BC Week In Review  |  Company News

Advanced Viral deal

ADVR acquired two cancer compounds and affinity based purification ( AFP) high throughput drug screening technology from Vincent Gullo and Dallas Hughes, the founding scientists of Cetek Corp. (Marlborough, Mass.). ADVR also will receive...
07:00 , Oct 8, 2007 |  BC Week In Review  |  Clinical News

AVR118: Phase II started

ADVR began an open-label, Canadian Phase II trial in 14 cancer patients to evaluate 4 ml doses of subcutaneous AVR118 given once daily for 28 days. Pending preliminary data from this first cohort, up to...
07:00 , Sep 10, 2007 |  BC Week In Review  |  Clinical News

AVR118: Phase II start

ADVR plans to start a Phase II trial of AVR118 in 14 cancer patients with cachexia-related symptoms. Pending the results from this first cohort, the trial could enroll at least 32 patients. Advanced Viral Research...